Clinical Trials Directory
We are doing this study to better understand women's preferences for and concerns about hormone replacement. We want to learn from women who have had their fallopian tubes and ovaries removed due to BRCA1 and BRCA2 mutations.
We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.
This study has three parts: 1. Getting Ready (Screening) - Takes up to 28 days - You'll get blood tests, a tissue sample, a TB test, and health checkups like scans and heart tests. 2. Treatment (Study Dosing) - People are grouped by race - You'll be randomly picked to get either regular chemo or chemo plus a study medicine (tocilizumab) - Medicine is given every 4 weeks - You'll keep doing health checkups and answer questions. 3. After Treatment (Follow-up) - Happens within 30 days after your last dose - More health checkups and questions to see how you're doing.
This study has three parts: 1. Screening Period (about 10 days): You will go to the clinic for tests like a brain scan (MRI), blood tests, heart check (EKG), and physical and brain exams. 2. Study Dosing Period: You will get a medicine called BRiTE through a small tube in your vein using a portable pump. It will run for 4 days. Then, you will not get any medicine for 24 days. This is called one cycle. You will go through 3 cycles like this. 3. Follow-Up Period: Doctors will keep checking on you with exams, blood tests, heart checks, and brain scans. You will visit the clinic every 8 weeks to make sure everything is going well.
In this study, people will take a medicine called R289 by mouth once or twice a day. The study has two parts: one part is to find the best dose, and the other part is to test two different doses. You may take the medicine at home or at the clinic. You will visit the clinic regularly for tests like blood work, physical check-ups, and heart exams. Some visits may take up to 8 hours. You can stay in the study as long as the medicine is helping and the side effects are not too strong.
Before starting treatment, patients will have tests and check-ups for up to 4 weeks. Then, treatment happens in cycles that last 6 weeks. Most people will have up to six cycles. After treatment, doctors will check on patients for about 3 years with visits every 12 weeks. Some early visits may take a long time, up to 6 to 12 hours. There are different groups in the study: - Doublet group: Gets two medicines (AMO959 and AAA617). - Triplet group: Gets three medicines (AMO959, AAA617, and ARPI). - Food-effect group: Tests how food changes AMO959 levels. In each cycle, AAA617 is given on Day 1. AMO959 is taken twice a day from Day 2 to Day 15. The triplet group also takes ARPI every day. The study is open-label, which means you and the doctors know which treatment you are getting. Patients will have regular visits, blood and urine tests, heart checks (ECGs), and scans like CT, MRI, bone scans, and PSMA-PET.
In this study, emergency room doctors and advanced practice providers will take part in special training to learn how to use heart and lung ultrasound. The training includes lessons and hands on practice using simulations. The training program is created together with hospital leaders and ultrasound experts. After the training, participants will use ultrasound during normal patient care to check the hearts and lungs of patients who have acute heart failure, following standard care guidelines.